ImmunityBio (IBRX) Capital Expenditures (2014 - 2026)

ImmunityBio (IBRX) has reported Capital Expenditures for 13 consecutive years, with $1.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Capital Expenditures changed N/A year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $2.4 million (up 1673.2% YoY), while the FY2025 annual figure was $1.4 million, up 22.29% from the prior year.
• Capital Expenditures rose to $1.1 million in Q1 2026 per IBRX's latest filing, from $792000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $43.4 million in Q2 2022 and bottomed at -$12.7 million in Q4 2023.
• Historically, Capital Expenditures has averaged $5.0 million across 5 years, with a median of $1.2 million in 2024.
• Annual changes were most pronounced in 2022 — Capital Expenditures soared 63919.12% — and 2025, when it slumped 191.98%.
• ImmunityBio's Capital Expenditures stood at $18.9 million in 2022, then tumbled by 166.91% to -$12.7 million in 2023, then jumped by 71.03% to -$3.7 million in 2024, then soared by 121.59% to $792000.0 in 2025, then jumped by 32.83% to $1.1 million in 2026.
• Business Quant data shows IBRX's Capital Expenditures at $1.1 million in Q1 2026, $792000.0 in Q4 2025, and -$1.6 million in Q3 2025.